Business context and reporting period
Important entity discrepancy: Although the request identifies Profusa, Inc., the supplied filing is NorthView Acquisition Corp.’s unaudited Form 10-Q for the quarter ended March 31, 2022. The filing describes NorthView as a blank-check company seeking a business combination, with a stated focus on healthcare innovation; it does not identify Profusa as the registrant or a target.
NorthView completed its IPO in December 2021 and had not selected a target or commenced operating activities by quarter-end. Accordingly, it reported no revenue. Financial results cover the three months ended March 31, 2022; the balance sheet compares March 31, 2022 with December 31, 2021.
Financial results and condition
| Metric | Q1 2022 / March 31, 2022 |
|---|---|
| Revenue | None |
| Formation and operating costs | $241,596 |
| Interest income on trust assets | $72,684 |
| Gain from change in warrant fair value | $3,877,929 |
| Net income | $3,709,017; basic and diluted EPS of $0.15 for each share category |
| Operating cash flow | $(230,352); cash declined from $741,228 to $510,876 |
| Cash and working capital | Approximately $0.5 million cash and $0.8 million working capital, per management |
| Trust assets | $191,726,645 carrying value; $191,587,347 fair value of trust investments disclosed |
| Total assets / total liabilities | $192,870,968 / $3,423,681 |
| Debt | No long-term debt or outstanding working-capital loans |
The reported profit was driven principally by a noncash decrease in the fair value of warrant liabilities, which fell from $7,216,022 at December 31, 2021 to $3,338,093 at March 31, 2022. It should not be interpreted as operating profitability. The filing does not provide a clear comparable prior-year-quarter income or cash-flow value.
Material changes, outlook, and risks
- Cash decreased by $230,352 during the quarter, while warrant liabilities declined by $3,877,929. The balance-sheet comparison shows total assets down from $193.1 million to $192.9 million and stockholders’ deficit narrowing from $5.9 million to $2.2 million, largely reflecting the quarter’s warrant revaluation gain.
- NorthView had until March 22, 2023 to complete a business combination, with possible extensions up to 21 months from the IPO closing if sponsor-funded deposits are made. Failure to complete a transaction would require liquidation and dissolution; management stated this creates substantial doubt about the company’s ability to continue as a going concern for the next 12 months.
- Management said additional working-capital loans may be available from insiders, but they are not obligated to provide them. No such loans were outstanding at quarter-end.
- The company reported no off-balance-sheet arrangements, long-term debt, or legal proceedings. It accrued and paid $15,000 in quarterly administrative-service fees. A $6,986,250 business-combination marketing fee would be payable upon completion of a transaction.
- Management cited potential adverse effects from COVID-19 and the Russia-Ukraine war, whose specific impacts were not determinable. The filing also notes proposed SEC SPAC rules that could increase transaction disclosure, costs, timing, and liability risks, and potentially affect the ability to complete a combination.
- Management reported disclosure controls and procedures were effective as of March 31, 2022, with no material quarterly change in internal control over financial reporting.
Most important facts to verify
- Confirm the intended issuer: the supplied 10-Q is for NorthView Acquisition Corp., not Profusa, Inc.
- Verify the SPAC’s business-combination status and timing against subsequent filings; no target had been selected in this report.
- Assess liquidity outside the trust account and whether sponsor or other financing is available to fund transaction costs through the deadline.
- Distinguish recurring operating performance from the noncash warrant fair-value gain that produced reported net income.
- Review the trust balance, redemption terms, extension funding requirements, and transaction-related fees and dilution before evaluating potential shareholder proceeds.